Loading clinical trials...
Loading clinical trials...
Multi-center Phase II Trial of Nimotuzumab Plus Irinotecan in Patients With High EGFR Expression After Failure of First-line Treatment in Recurrent or Metastatic Gastric Adenocarcinoma（NIEGA）
Conditions
Interventions
Irinotecan
nimotuzumab
Locations
1
China
Peking cancer hospital
Beijing, Beijing Municipality, China
Start Date
June 1, 2015
Primary Completion Date
June 1, 2018
Completion Date
June 1, 2018
Last Updated
January 17, 2018
NCT06885697
NCT06630130
NCT07035587
NCT01649271
NCT02310230
NCT06260150
Lead Sponsor
Peking University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions